Sugi Predict

Sugi Predict / Compounds / SCHEMBL1507449

SCHEMBL1507449

SCHEMBL1507449

C#Cc1cc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)ccc1F

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 15/20 0.80
▸ ILK Q13418 3/20 0.80
▸ FBP1 P09467 1/20 0.79
▸ ERBB2 P04626 5/20 0.78
▸ KDR P35968 3/20 0.68
▸ KDM1A O60341 2/20 0.68
▸ FLT1 P17948 2/20 0.68
▸ PLK4 O00444 1/20 0.68
▸ CIT O14578 1/20 0.68
▸ AURKA O14965 1/20 0.68
▸ GAK O14976 1/20 0.68
▸ EPHB6 O15197 1/20 0.68
▸ SLC22A1 O15245 1/20 0.68
▸ DAPK3 O43293 1/20 0.68
▸ RIPK2 O43353 1/20 0.68
▸ BUB1 O43683 1/20 0.68
▸ JAK2 O60674 1/20 0.68
▸ RPS6KA4 O75676 1/20 0.68
▸ STK17B O94768 1/20 0.68
▸ STK10 O94804 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2615523 1.00 EGFR (0.80) EGFRILKFBP1ERBB2KDR
Hydrochloric Acid SCHEMBL1507642 0.99 EGFR (0.78) EGFRILKFBP1ERBB2KDR
SCHEMBL23264520 0.89 EGFR (1.00) EGFRILKFBP1ERBB2KDR
SCHEMBL1657530 0.89 EGFR (0.80) EGFRILKFBP1ERBB2ERBB4
SCHEMBL13646428 0.88 EGFR (0.70) EGFRILKFBP1ERBB2KDR
SCHEMBL14964660 0.88 EGFR (0.83) EGFRILKFBP1ERBB2KDR
SCHEMBL1507616 0.88 EGFR (1.00) EGFRILKFBP1ERBB2KDR
SCHEMBL8216602 0.88 ERBB2 (1.00) EGFRERBB2KDRGAKRIPK2
SCHEMBL3875759 0.88 EGFR (0.80) EGFRILKFBP1ERBB2KDR
SCHEMBL14481882 0.88 EGFR (0.80) EGFRILKFBP1ERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2016-10-20 — — US claimed
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2015-03-26 — — US claimed
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2015-02-26 — — US claimed
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS SLIWKOWSKI MARK X (US) 2012-10-04 — — US claimed
US-8163287-B2 Combination therapy of her expressing tumors GENENTECH, INC. (US) 2012-04-24 — — US claimed
EP-2344543-A2 TREATMENT METHOD Genentech, Inc. (US) 2011-07-20 — — EP claimed
JP-2011513427-A — — 2011-04-28 — — JP claimed
EP-2295415-A1 Quinazoline derivatives OSI Pharmaceuticals, Inc. (US) 2011-03-16 — — EP claimed
EP-2257293-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS Genentech, Inc. (US) 2010-12-08 — — EP claimed
WO-2010045345-A2 TREATMENT METHOD GENENTECH, INC. (US) 2010-04-22 — — WO claimed
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-10 — — US claimed
US-20080175797-A1 PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-07-24 — — US claimed
WO-2007013950-A9 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH INC (US) 2007-03-29 — — WO claimed
WO-2007013950-A2 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2007-02-01 — — WO claimed
US-20070020261-A1 Combination therapy of her expressing tumors GENENTECH, INC. 2007-01-25 — — US claimed
EP-0817775-B1 QUINAZOLINE DERIVATIVES PFIZER (US) 2001-09-12 — — EP claimed
EP-1110953-A1 Quinazoline derivatives PFIZER INC. (US) 2001-06-27 — — EP claimed
US-5747498-A Alkynyl and azido-substituted 4-anilinoquinazolines PFIZER INC. (US) 1998-05-05 — — US claimed
EP-0817775-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1998-01-14 — — EP claimed
WO-1996030347-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1996-10-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885ILK 3200/4885FBP1 2318/4885
US-20070020261-A1 Combination therapy of her expressing tumors ERBB2, EGFR, ERBB3 EGFR 2/4885ILK 3200/4885FBP1 2318/4885
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ILK 2655/4885FBP1 3214/4885
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ILK 2655/4885FBP1 3214/4885
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ILK 2655/4885FBP1 3214/4885
US-20080175797-A1 PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS EGFR, MUC1, OGFR EGFR 1/4885ILK 3926/4885FBP1 3616/4885
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885ILK 3200/4885FBP1 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.